Management tracks: Immunomedics, Daiichi, Notable Labs

Immunomedics Inc. (NASDAQ:IMMU) said Michael Pehl resigned as president, CEO and a board member due to personal reasons, just 15 months after he joined the antibody-drug conjugate company. The news comes a month after FDA issued a complete response letter for a BLA for Immunomedics' sacituzumab govitecan (IMMU-132) to treat metastatic triple-negative breast cancer in a third-line setting (see "FDA Delays Approval of Immunomedics' ADC for Triple-Negative Breast Cancer").

Chairman Behzad Aghazadeh will become executive chairman, and board member Scott Canute will become executive director. Interim CFO Usama Malik will become CFO...